Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Short term Debt (2016 - 2025)

Coherus Oncology's Short term Debt history spans 8 years, with the latest figure at $26.2 million for Q1 2025.

  • For Q1 2025, Short term Debt changed N/A year-over-year to $26.2 million; the TTM value through Mar 2025 reached $26.2 million, changed N/A, while the annual FY2024 figure was $13.6 million, 312.73% up from the prior year.
  • Short term Debt for Q1 2025 was $26.2 million at Coherus Oncology, up from $13.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $26.2 million in Q1 2025 and bottomed at $90000.0 in Q2 2023.
  • The 4-year median for Short term Debt is $10.4 million (2021), against an average of $10.2 million.
  • The largest YoY upside for Short term Debt was 10124.44% in 2024 against a maximum downside of 312.73% in 2024.
  • A 4-year view of Short term Debt shows it stood at $17.3 million in 2021, then plummeted by 80.92% to $3.3 million in 2023, then surged by 312.73% to $13.6 million in 2024, then skyrocketed by 92.57% to $26.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Short term Debt are $26.2 million (Q1 2025), $13.6 million (Q4 2024), and $9.2 million (Q2 2024).